Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: June 2014

Eslicarbazepine acetate

Related content

Powered by UNSILO

Suggested reading

Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA- 2–093). Neurotherapeutics 2007; 4: 88–96.
Almeida L, Falcao A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2–093) in healthy elderly and young subjects. Journal of Clinical Pharmacology 2005; 45: 1062–1066.
Almeida L, Potgieter JH, Maia J, Potgieter MA, Moto F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. European Journal of Clinical Pharmacology 2008; 64: 267–273.
Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P, on behalf of the BIA-2093–301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo controlled, parallel-group phase III study. Epilepsia 2009; 50: 454–463.
Falcão A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. CNS Drugs 2012; 26: 79–91.
Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P, on behalf of the BIA-2093–303 Investigators Study Group. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurologica Scandinavica 2009; 120: 281–287.
Gil-Nagel A, Elger C, Ben-Menachem E, Halász P, Lopes-Lima J, Gabbai AA, Nunes T, Falcão A, Almeida L, da-Silva PS. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia 2013; 54: 98–107.
Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119–140.
Meis J, Almeida L, Falcao A, Soares E, Mota F, Potgieter MA, Potgieter JH, Soares-da-Silva P. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. International Journal of Clinical Pharmacology and Therapeutics 2008; 463: 119–130.
Patsalos PN. Antiepileptic drug interactions: a clinical guide, 2nd edition. 2013, Springer, London, UK; 2013.
Patsalos PN, Berry DJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opinion in Pharmacotherapy, 2012; 13:699–715.
Perucca E, Elger C, Halász P, Falcão A, Almeida L, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Research 2011; 96:132–1329.